You're right, it makes no sense to file the 3rd quarter 10-Q, until the 2nd quarter 10-Q is filed, which I think Durrant has already prepared, with the possible exception of accounting for the Baudax transaction. I assume both Q's will be filed. And I further agree with you that management seems to be less concerned with financial constraints (or perhaps they wouldn't have purchased the Baudax shares on the last day of Q2). And the toughest thing about the current price per share is that we can't buy more shares at these prices.
In terms of thinking that something is up here, I think that "something" is the pending recall of our loaned shares, possibly announcing that the company owns over 90% of their issued shares.
In terms of bang for the buck, the recall will have a much bigger impact on share price than news of regulatory approvals, business combinations, mergers, PRV's, the forward stock split, or product purchase orders, including stockpile orders. But as borrowed shares become purchased, the share recall will have accomplished it's purpose, and the other catalysts will determine our sustained operational value. I previously mentioned a projected Market Cap of $8B for us. I wouldn't be surprised if it is lower...nor would I be surprised if it was higher.
Your post was excellent!
News 
Market Data 
Discover 
